The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
It promises fewer injections for vision loss patients
The company plans to submit the vaccine for regulatory review
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
Subscribe To Our Newsletter & Stay Updated
